BOK Financial’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.2M Sell
136,461
-21,809
-14% -$2.87M 0.24% 84
2026
Q1
$22.1M Buy
158,270
+42,516
+37% +$5.95M 0.34% 63
2025
Q4
$14.2M Buy
115,754
+1,998
+2% +$243K 0.22% 91
2025
Q3
$12.6M Buy
113,756
+9,926
+10% +$1.13M 0.19% 107
2025
Q2
$11.5M Sell
103,830
-877
-0.8% -$93.3K 0.19% 106
2025
Q1
$11.7M Sell
104,707
-3,834
-4% -$396K 0.21% 97
2024
Q4
$9.76M Buy
108,541
+1,966
+2% +$177K 0.16% 115
2024
Q3
$8.97M Sell
106,575
-5,959
-5% -$455K 0.16% 131
2024
Q2
$7.72M Sell
112,534
-11,899
-10% -$794K 0.14% 146
2024
Q1
$9.07M Buy
124,433
+9,276
+8% +$713K 0.17% 130
2023
Q4
$9.33M Sell
115,157
-1,341
-1% -$104K 0.18% 119
2023
Q3
$9.15M Buy
116,498
+4,529
+4% +$348K 0.2% 111
2023
Q2
$8.63M Sell
111,969
-3,813
-3% -$304K 0.18% 127
2023
Q1
$9.61M Sell
115,782
-6,567
-5% -$544K 0.2% 114
2022
Q4
$10.5M Sell
122,349
-1,982
-2% -$157K 0.19% 113
2022
Q3
$7.67M Sell
124,331
-8,982
-7% -$566K 0.16% 138
2022
Q2
$8.24M Buy
133,313
+896
+0.7% +$55.5K 0.16% 145
2022
Q1
$7.87M Buy
132,417
+9,630
+8% +$616K 0.13% 164
2021
Q4
$8.91M Buy
122,787
+50,642
+70% +$3.49M 0.14% 159
2021
Q3
$5.04M Buy
+72,145
New +$5.07M 0.09% 225
2021
Q1
$3.92M Sell
60,628
-41,008
-40% -$2.64M 0.07% 261
2020
Q4
$5.92M Sell
101,636
-37,585
-27% -$2.27M 0.11% 181
2020
Q3
$8.8M Sell
139,221
-21,265
-13% -$1.47M 0.19% 116
2020
Q2
$12.3M Buy
160,486
+35,394
+28% +$2.71M 0.29% 85
2020
Q1
$9.35M Sell
125,092
-10,213
-8% -$706K 0.27% 94
2019
Q4
$8.79M Buy
135,305
+2,606
+2% +$170K 0.2% 122
2019
Q3
$8.41M Buy
132,699
+36,348
+38% +$2.38M 0.2% 113
2019
Q2
$6.51M Buy
96,351
+108
+0.1% +$7.11K 0.16% 161
2019
Q1
$6.26M Buy
96,243
+7,078
+8% +$470K 0.15% 159
2018
Q4
$5.58M Sell
89,165
-18,222
-17% -$1.27M 0.16% 143
2018
Q3
$8.29M Sell
107,387
-13,548
-11% -$1.02M 0.21% 113
2018
Q2
$8.57M Buy
120,935
+2,146
+2% +$152K 0.23% 106
2018
Q1
$8.96M Sell
118,789
-1,005
-0.8% -$79.9K 0.25% 97
2017
Q4
$8.58M Buy
119,794
+21,768
+22% +$1.65M 0.24% 106
2017
Q3
$7.94M Buy
98,026
+48,634
+98% +$3.72M 0.23% 105
2017
Q2
$3.5M Sell
49,392
-5,914
-11% -$394K 0.11% 210
2017
Q1
$3.76M Sell
55,306
-1,573
-3% -$111K 0.12% 198
2016
Q4
$4.07M Sell
56,879
-1,956
-3% -$145K 0.13% 175
2016
Q3
$4.66M Sell
58,835
-2,134
-4% -$173K 0.15% 154
2016
Q2
$5.09M Sell
60,969
-3,378
-5% -$300K 0.18% 127
2016
Q1
$5.91M Buy
64,347
+230
+0.4% +$20.7K 0.21% 110
2015
Q4
$6.49M Sell
64,117
-22,857
-26% -$2.38M 0.23% 102
2015
Q3
$8.54M Sell
86,974
-3,002
-3% -$333K 0.32% 72
2015
Q2
$10.5M Buy
89,976
+12,906
+17% +$1.41M 0.36% 67
2015
Q1
$7.56M Buy
77,070
+10,991
+17% +$1.12M 0.25% 95
2014
Q4
$6.23M Sell
66,079
-10,091
-13% -$1.04M 0.22% 112
2014
Q3
$8.11M Sell
76,170
-11,991
-14% -$1.17M 0.27% 85
2014
Q2
$7.31M Buy
88,161
+7,434
+9% +$579K 0.23% 95
2014
Q1
$5.72M Buy
80,727
+28,094
+53% +$2.2M 0.19% 123
2013
Q4
$3.95M Buy
52,633
+8,227
+19% +$573K 0.13% 166
2013
Q3
$2.79M Buy
44,406
+15,624
+54% +$934K 0.1% 221
2013
Q2
$1.48M Buy
+28,782
New +$1.5M 0.06% 326

Other funds holding GILD

BOK Financial's GILD Position: Q2 2026 in Review

BOK Financial reduced its Gilead Sciences (GILD) stake by 14% in Q2 2026, selling an estimated $2.87M and leaving 136,461 shares worth $17.2M. The position accounts for 0.24% of the portfolio, ranked #84.

BOK Financial first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $22.1M in Q1 2026. 2,265 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • BOK Financial held 136,461 shares of Gilead Sciences worth $17.2M as of Q2 2026.
  • BOK Financial sold 21,809 Gilead Sciences shares in Q2 2026, an estimated $2.87M.
  • Gilead Sciences made up 0.24% of BOK Financial's portfolio in Q2 2026, its #84 holding.
  • BOK Financial first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • BOK Financial's Gilead Sciences position peaked at $22.1M in Q1 2026.
  • 2,265 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on BOK Financial's 13F filing for Q2 2026, filed 10 Aug 2026.